TY - JOUR T1 - <strong>Clinical Predictors of <sup>18</sup>F-Sodium Fluoride PET Coronary Uptake in Patients with Advanced Coronary Artery Disease</strong> JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 87 LP - 87 VL - 61 IS - supplement 1 AU - Jacek Kwiecinski AU - Evangelos Tzolos AU - Philip Adamson AU - Sebastien Cadet AU - Alastair Moss AU - Nikhil Joshi AU - Michelle Williams AU - Edwin van Beek AU - Damini Dey AU - David Newby AU - Daniel Berman AU - Marc Dweck AU - Piotr Slomka Y1 - 2020/05/01 UR - http://jnm.snmjournals.org/content/61/supplement_1/87.abstract N2 - 87Objectives: 18F-sodium fluoride (18F-NaF) PET depicts developing microcalcifications in the vasculature, serving as a marker of disease activity in patients with established coronary artery disease (CAD), and providing independent prediction of myocardial infarction. To date the associations in 18F-NaF coronary activity and the risk of adverse events assessed using risk scores dedicated for prediction of recurrent cardiovascular events is not well characterized, hence the clinical rationale for performing coronary PET imaging is not yet established. In this study we investigated the relationship between 18F-NaF coronary uptake and clinical variables, as well as risk scores developed for estimating the risk of recurrent events in patients with established cardiovascular disease: REACH [Reduction of Atherothrombosis for Continued Health] and SMART [Secondary Manifestations of Arterial Disease]. Methods: Patients with known CAD underwent a 30 min single bed position 18F-NaF PET and CT angiography 1h after a 6.8 mCI injection of 18F-NaF on a hybrid PET/CT scanner. We assessed coronary 18F-NaF uptake using whole-vessel tubular and tortuous 3D volumes of interest (VOI) along the vessel centerlines, which were automatically extracted from CT angiography datasets. Within such VOIs the coronary microcalcification activity (CMA) was defined as the integrated activity in standard uptake value (SUV) units exceeding the background in the left atrium blood pool SUVmean+2 standard deviations (Figure 1). We used a previously established 1.56 CMA threshold to distinguish patients with low and high coronary 18F-NaF uptake. Results: Among 293 study participants (65±9 years; 84% male) 237 (81%) had a history of revascularization, 191 (65%) had multi-vessel obstructive CAD and the median coronary calcium score was 334 [76-804]. Overall 109 (37.2%) patients presented with high 18F-NaF activity. There was no difference in the presence of comorbidities (diabetes, hypertension, hyperlipidemia), smoking or history of percutaneous coronary interventions between subjects with high and low 18F-NaF activity, all p&gt;0.50. Similarly, there was no difference in the SMART and REACH scores according to 18F-NaF uptake: 20.2 ±10.0 vs 20.8±10.7, p=0.64 and 12.7±3.0 vs 13.3±2.7, p=0.24. On univariate regression analysis both the SMART and REACH scores emerged as predictors of 18F-NaF activity, yet the predictive capacity was very low r2=0.038, p=0.001 and r2=0.02, p=0.016 respectively. Conclusions: In patients with established, advanced CAD there is no difference in comorbidities and clinical risk scores between patients with a high and low CMA as evidenced by 18F-NaF PET. While both 18F-NaF and risk scores have been shown to predict adverse events, the assessment of CMA appears to provide complementary information to the SMART and REACH models. ER -